ACB
Price
$4.90
Change
+$0.07 (+1.45%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
276.48M
61 days until earnings call
TLRY
Price
$1.19
Change
+$0.03 (+2.61%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
1.26B
27 days until earnings call
Interact to see
Advertisement

ACB vs TLRY

Header iconACB vs TLRY Comparison
Open Charts ACB vs TLRYBanner chart's image
Aurora Cannabis
Price$4.90
Change+$0.07 (+1.45%)
Volume$21.18K
Capitalization276.48M
Tilray Brands
Price$1.19
Change+$0.03 (+2.61%)
Volume$149.15K
Capitalization1.26B
ACB vs TLRY Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. TLRY commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a StrongBuy and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ACB: $4.91 vs. TLRY: $1.15)
Brand notoriety: ACB and TLRY are both notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 56% vs. TLRY: 64%
Market capitalization -- ACB: $276.48M vs. TLRY: $1.26B
ACB [@Pharmaceuticals: Generic] is valued at $276.48M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $1.26B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, TLRY is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 6 TA indicator(s) are bullish while TLRY’s TA Score has 3 bullish TA indicator(s).

  • ACB’s TA Score: 6 bullish, 5 bearish.
  • TLRY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ACB is a better buy in the short-term than TLRY.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а -9.41% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was -21.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

ACB is expected to report earnings on Nov 06, 2025.

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.26B) has a higher market cap than ACB($276M). ACB YTD gains are higher at: 15.529 vs. TLRY (-13.534). ACB has higher annual earnings (EBITDA): 26.6M vs. TLRY (-2.13B). TLRY has more cash in the bank: 256M vs. ACB (140M). ACB has less debt than TLRY: ACB (102M) vs TLRY (329M). TLRY has higher revenues than ACB: TLRY (821M) vs ACB (358M).
ACBTLRYACB / TLRY
Capitalization276M1.26B22%
EBITDA26.6M-2.13B-1%
Gain YTD15.529-13.534-115%
P/E Ratio19.44N/A-
Revenue358M821M44%
Total Cash140M256M55%
Total Debt102M329M31%
FUNDAMENTALS RATINGS
ACB vs TLRY: Fundamental Ratings
ACB
TLRY
OUTLOOK RATING
1..100
2182
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9399
PRICE GROWTH RATING
1..100
5935
P/E GROWTH RATING
1..100
9194
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (52) in the Biotechnology industry is in the same range as ACB (58) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to ACB’s over the last 12 months.

TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to ACB’s over the last 12 months.

ACB's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as TLRY (99) in the Biotechnology industry. This means that ACB’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's Price Growth Rating (35) in the Biotechnology industry is in the same range as ACB (59) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to ACB’s over the last 12 months.

ACB's P/E Growth Rating (91) in the Pharmaceuticals Other industry is in the same range as TLRY (94) in the Biotechnology industry. This means that ACB’s stock grew similarly to TLRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBTLRY
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 11 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JHURX35.48N/A
N/A
JPMorgan Emerging Markets Equity R3
ONERX56.58N/A
N/A
One Rock
PGINX25.53N/A
N/A
Impax Global Environmental Markets Instl
VCGRX23.72N/A
N/A
Virtus KAR Capital Growth R6
GVIZX12.55N/A
N/A
GuideStone Funds Value Equity Index Inv

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been closely correlated with SNDL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
-2.95%
SNDL - TLRY
76%
Closely correlated
-3.17%
CGC - TLRY
63%
Loosely correlated
-1.43%
OGI - TLRY
61%
Loosely correlated
-0.62%
CRON - TLRY
60%
Loosely correlated
-1.19%
ACB - TLRY
56%
Loosely correlated
-1.63%
More